HDAC9 and cancer: Significantly, a clinically well-tolerated HDAC inhibitor called quisinostat has recently demonstrated the ability to effectively restore H1.0 levels in various patient-derived cancer cell lines, as well as a significant impairment of self-renewal capacity in breast and non-small lung cancer cell models [75].